Prostate-specific membrane antigen (PSMA) gene expression predicts angiogenesis and response to tyrosine kinase inhibitors (TKIs) in patients with metastatic clear cell renal cell carcinoma (RCC), ...

Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited tumor-infiltrating lymphocytes (TILs) may be ...

Dr. Hyung L. Kim discusses how the addition of cytoreductive nephrectomy to ICI therapy may affect survival and quality of ...

During a live event, Martin Voss, MD, reviewed the trials of lenvatinib plus pembrolizumab, cabozantinib plus nivolumab, and ipilimumab plus nivolumab in non–clear cell renal cell carcinoma ...

Current evidence shows limited benefit from additional immunotherapy in renal cell carcinoma patients previously treated with immune checkpoint inhibitors. Two large randomized trials yielded negative ...

Metastatic castration-resistant prostate cancer (mCRPC) is an advanced form of prostate cancer. Metastatic means the cancer has spread from the prostate to other parts of the body, like the bones, ...

Purpose: The role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma (mRCC) is reviewed. Conclusion: The tyrosine kinase inhibitors sorafenib and sunitinib offer ...

As many as 53,000 American men are diagnosed with bladder cancer each year, while over 10,000 are expected to die as a result of the malignancy. By far the most common bladder cancer in the United ...

April 16, 2025 A Nationwide Real-world Evaluation of Upfront Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma in the Immunotherapy Era. April 15, 2025 ...

First approval in the EU for Daiichi Sankyo and AstraZeneca’s DATROWAY based on TROPION-Breast01 trial showing 37% reduction in the risk of disease progression or death versus chemotherapy ...

Patients were stratified by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk groups: favorable vs intermediate vs poor. The trial was designed to reach 80% power with 385 ...